相关实验视频
Updated: Feb 15, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
使用临床数据和代谢学来开发和验证残留肺血管阻塞的风险预测模型
Xue Xu1, Xiaoyu Cheng1, Guiyin Zhu1
1Department of Respiratory Medicine, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China.
残留性肺血管阻塞 (RPVO) 与糟糕的结局有关. 结合临床因素和代谢物 (如azelaic acid) 的新模型可以识别高风险患者,以获得更好的抗凝治疗.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 代谢学 代谢学 代谢学
背景情况:
- 残留性肺血管阻塞 (RPVO) 是已知的静脉血栓栓塞 (VTE) 复发和不良预后的风险因素.
- 然而,RPVO的特定风险因素和预后影响需要进一步澄清.
研究的目的:
- 开发用于识别高风险RPVO患者的预测模型.
- 整合临床和代谢生物标志物,以提高风险分层.
- 为优化急性肺栓塞 (APE) 患者的抗凝固疗法提供指导.
主要方法:
- 追溯分析363名APE患者的随访情况.
- 开发和验证全面和简化的RPVO预测模型.
- 从基线血液样本中纳入代谢生物标志物,并在潜在队列中进行验证.
主要成果:
- 确定了五个独立的RPVO预测因素:V/Q扫描上受影响的叶片,sPESI得分,肺动脉压力,最近的手术/固定和活跃的癌症.
- 预测模型在培训,验证和潜在队列中表现出极好的歧视.
- 青酸和L-3-乳酸是关键的差异化代谢物,提高了模型的性能. RPVO和广泛的肺部参与预测了不良结果.
结论:
- 开发并验证了使用临床和代谢生物标志物的全面和简化RPVO预测模型.
- 包含azelaic acid和L-3-phenyl乳酸的模型显著提高了性能.
- RPVO独立预测不良结果,强调了联合临床和分子分析的价值.
更多相关视频
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
相关概念视频
Data Validation
Key parameters for method validation include:
Data Validation
Nursing assessment guides are generally based on holistic models rather than medical...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation